Literature DB >> 11981322

Autoantigenic posttranslational modifications of proteins: does it apply to rheumatoid arthritis?

ZhiJie Zhou1, Henri-André Ménard.   

Abstract

There are many posttranslational modifications of proteins of which all are homeostatically important either to carry out a particular structural or functional role or to allow efficient recycling of the amino acid constituents. An important feature of the modified proteins is the acquisition of autoantigenicity. That notion should have been recognized for years with the modifications of immunoglobulin G that constitute new targets for rheumatoid factors. Citrullination or the deimination of arginine residues in proteins creates epitopes that are targeted by rheumatoid autoantibodies with a diagnostic sensitivity and specificity of 40% to 70% and 92% to 99%, respectively. The how, when, and why of the responsible break in tolerance are largely speculative but apoptosis, multiple genetic and environmental influences are likely required. Identifying citrullinated proteins as autoantigens has resulted in new diagnostic and prognostic autoantibody markers for RA and studying the citrullination process and its nature and role in cell biology has provided new insights into its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981322     DOI: 10.1097/00002281-200205000-00010

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  12 in total

1.  Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis.

Authors:  Mesut Ogrendik; Siranus Kokino; Ferda Ozdemir; Philip S Bird; Stephen Hamlet
Journal:  MedGenMed       Date:  2005-06-16

2.  Association between susceptibility to rheumatoid arthritis and PADI4 polymorphisms: a meta-analysis.

Authors:  Young Ho Lee; Sang-Cheol Bae
Journal:  Clin Rheumatol       Date:  2015-10-16       Impact factor: 2.980

3.  Treatment of rheumatoid arthritis with ornidazole: a randomized, double-blind, placebo-controlled study.

Authors:  Mesut Ogrendik
Journal:  Rheumatol Int       Date:  2006-06-13       Impact factor: 2.631

4.  T cell responses to citrullinated self-peptides in patients with rheumatoid arthritis.

Authors:  Amita Aggarwal; Rajni Srivastava; Suraksha Agrawal
Journal:  Rheumatol Int       Date:  2013-03-31       Impact factor: 2.631

5.  Bispecific abs against modified protein and DNA with oxidized lipids.

Authors:  Mitsugu Akagawa; Sohei Ito; Kazuyo Toyoda; Yoshihisa Ishii; Emi Tatsuda; Takahiro Shibata; Satoru Yamaguchi; Yoshichika Kawai; Kousuke Ishino; Yusuke Kishi; Takahiro Adachi; Takeshi Tsubata; Yoshinari Takasaki; Nobutaka Hattori; Tsukasa Matsuda; Koji Uchida
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-07       Impact factor: 11.205

6.  Autoimmunity to citrullinated type II collagen in rheumatoid arthritis.

Authors:  Mamoru Yoshida; Michiko Tsuji; Daitaro Kurosaka; Daisaburo Kurosaka; Jun Yasuda; Yoshitaka Ito; Tetsuro Nishizawa; Akio Yamada
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

Review 7.  Current concepts in normal and defective angiogenesis: implications for systemic sclerosis.

Authors:  Mary Jo Mulligan-Kehoe; Michael Simons
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

8.  Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritis.

Authors:  A Barton; J Bowes; S Eyre; D Symmons; J Worthington; A Silman
Journal:  Ann Rheum Dis       Date:  2005-02-24       Impact factor: 19.103

9.  Frequency of serological markers of rheumatoid arthritis in adult patients with active celiac disease.

Authors:  Mariam Ghozzi; Sarra Melayah; Najeh Adaily; Ibtissem Ghedira
Journal:  J Clin Lab Anal       Date:  2022-01-20       Impact factor: 2.352

10.  PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis.

Authors:  Young Ho Lee; Young Hee Rho; Seong Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2007-01-31       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.